Communiqués Fennec Pharmaceuticals Inc. Toronto S.E.

Actions

FRX

CA31447P1009

Produits pharmaceutiques

Temps Différé Toronto S.E. 15:30:01 08/09/2026			Varia. 5j.	Varia. 1 janv.
17,10 ^CAD	-1,84 %		+0,59 %	+61,32 %

12/08	Fennec Pharmaceuticals Inc. : B. Riley reste à l'achat	ZM
11/08	Fennec Pharmaceuticals au plus haut depuis plusieurs années après un retour aux bénéfices supérieur aux attentes au deuxième trimestre	MT

Communiqués

11/08	Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update	GL
05/08	Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026	GL
22/06	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	GL
16/06	Fennec Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)	AQ
15/06	Fennec Pharmaceuticals : Announces Results of Annual Meeting	PU
15/06	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	GL
10/06	Fennec Announces Results of Annual Meeting	GL
22/05	Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting	GL
18/05	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
18/05	Fennec Pharmaceuticals : Corporate Presentation May 2026	PU
14/05	Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update	GL
08/05	Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026	AQ
07/05	Fennec Pharmaceuticals : Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting	PU
07/05	Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026	GL
21/04	Fennec Pharmaceuticals : Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center	PU
21/04	Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting	GL
07/04	Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center	GL
31/03	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
31/03	Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
24/03	Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses	NE
24/03	Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	GL
18/03	Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026	GL
16/03	Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation	GL
04/03	Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute	AQ
20/02	Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers	GL